Beyond conventional imaging, new screening approaches are emerging to improve early lung cancer detection. A urine-based testing solution developed by Vitae Biomedical Co., Ltd. offers a non-invasive alternative, achieving approximately 90% accuracy while providing clinicians with an additional tool for risk assessment.

While low-dose computed tomography (LDCT) remains the standard for lung cancer screening, its accessibility is often limited to high-risk populations and designated medical facilities. Concerns about radiation exposure and logistical barriers also prevent broader adoption. These challenges have led to growing interest in more accessible and patient-friendly screening options.

Founded in 2019, Vitae Biomedical initially focused on developing targeted therapies. During early research, the team identified significant differences in specific biomarker levels in the urine of lung cancer patients compared to healthy individuals. This discovery led to a strategic pivot toward developing a urine-based detection approach as a more scalable pathway to early clinical impact.

The test itself is designed to be simple and accessible. Sample collection is non-invasive and can be performed without specialized procedures, with results available within approximately one week. Through continuous optimization, the platform has improved from an initial accuracy of around 70–80% to approximately 90% today.

Key technological advancements include the development of highly specific antibodies and an enhanced ELISA-based detection design that requires dual confirmation signals, significantly reducing false positives. In addition, the integration of patient-specific parameters—such as age, gender, and health conditions—combined with AI-driven analysis further improves diagnostic precision over time.

Clinical collaborations are currently underway with multiple leading medical centers in Taiwan, exploring various use cases, including early-stage screening, diagnostic support, and post-treatment monitoring. These efforts are helping define the most effective clinical positioning for the technology.

Beyond Taiwan, the company is actively expanding into international markets. Southeast Asia represents a key entry point due to limited access to advanced imaging infrastructure, where urine-based testing may serve as a practical first-line screening tool. The company is also preparing for expansion into Europe and the United States, supported by existing CE certification and ongoing clinical validation efforts, including studies in Europe.

Looking ahead, Vitae Biomedical is continuing to advance its technology platform, with future plans to develop portable, point-of-care devices and personalized health monitoring solutions. By combining non-invasive testing with data-driven insights, the company aims to contribute to the broader shift toward precision medicine and more accessible healthcare.